Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. scores highest on Earnings (66) and lowest on Price (37). Its PosiPenta is 55.43 out of 100, around the middle of similar companies.
On the Penta Grid this week, Sarepta Therapeutics, Inc. is Grid #206 of 837 in the Healthcare sector in United States, and Grid #1,199 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc. | 55.43 | 37 | 66 | 62 | 48 | 64 |
| Astrana Health, Inc. | 62.30 | 38 | 88 | 75 | 47 | 64 |
| ADARx Pharmaceuticals, Inc. | 46.78 | 0 | 46 | 61 | 56 | 71 |
| BioLife Solutions Inc | 58.21 | 30 | 47 | 97 | 74 | 44 |
| Establishment Labs Holdings Inc. | 38.04 | 1 | 62 | 58 | 10 | 59 |
| DENTSPLY SIRONA Inc. | 43.90 | 36 | 57 | 42 | 35 | 49 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -10.89 |
| P/B ratio | 1.18 |
EEarnings
| Trailing EPS | ₹-148.70 |
| Forward EPS | ₹227.41 |
NNitro
| Price | 1619.63 |
| 52-week high | 2337.57 |
| 52-week low | 1390.42 |
| Fall from 52-week high | 30.7% |
TTorque
| Return on equity (ROE) | -9.48% |
| Debt-to-equity | 0.70 |
AAnchor
| Beta (price swings) | 0.38 |
| Market cap | ₹17,107 Cr |
| Insider holding | 4.88% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Sarepta Therapeutics, Inc.'s PosiPenta score?
Sarepta Therapeutics, Inc.'s PosiPenta is 55.43 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Sarepta Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Sarepta Therapeutics, Inc. is Grid #206 of 837 in the Healthcare sector in United States, and Grid #1,199 of 4,000 in United States.
Which PosiPenta pillar is strongest for Sarepta Therapeutics, Inc.?
Earnings (growth), with a score of 66 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Sarepta Therapeutics, Inc.?
Price (valuation), with a score of 37 out of 100: weaker than most similar companies.
Has Sarepta Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 15.41 points, from 40.02 to 55.43.
PositoAI is for research and education only and is not investment advice.